Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3660018 | 0.84 | CHRNB2 (0.31) | — | |
| SCHEMBL427184 | 0.84 | HCAR2 (0.33) | HCAR2 | |
| SCHEMBL584540 | 0.83 | NPC1 (0.35) | HCAR2 | |
| SCHEMBL2067107 | 0.83 | KDM4E (0.32) | — | |
| SCHEMBL219239 | 0.81 | CYP11B1 (0.34) | — | |
| SCHEMBL17651864 | 0.80 | KDM4E (0.37) | — | |
| SCHEMBL3861990 | 0.80 | CYP11B1 (0.33) | — | |
| SCHEMBL1502646 | 0.80 | CYP19A1 (0.31) | — | |
| SCHEMBL113201 | 0.79 | — | — | |
| SCHEMBL1181193 | 0.79 | CYP11B2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| US-20220396553-A1 | NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-12-15 | — | — | US | disclosed |
| EP-3901139-A1 | NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2021-10-27 | — | — | EP | disclosed |
| EP-2614061-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2015-05-20 | — | — | EP | disclosed |
| US-9029392-B2 | Quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2015-05-12 | — | — | US | disclosed |
| US-20130296338-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-11-07 | — | — | US | disclosed |
| EP-2614061-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012032334-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | ATM 3283/4885HCAR2 2410/4885 |
| US-20130296338-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | MAP3K13, MAP4K3, MAP3K3 | ATM 466/4885HCAR2 2273/4885 |
| US-20220396553-A1 | NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF | AANAT, NAT1, HNMT | ATM 3670/4885HCAR2 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.